Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 24, 2025; 16(8): 107009
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.107009
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.107009
Survival benefits of concurrent immune checkpoint inhibitor and radiotherapy in non-small cell lung cancer with brain metastases
Xue-Jie Liu, Chun-Luan Yuan, Department of Oncology, The First People’s Hospital of Lianyungang, Lianyungang 222016, Jiangsu Province, China
Heng Ge, Department of Oncology, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450001, Henan Province, China
Co-corresponding authors: Heng Ge and Chun-Luan Yuan.
Author contributions: Liu XJ and Yuan CL participated in the conception and design of the study, wrote the manuscript, accessed and verified the study data; Liu XJ, Ge H, and Yuan CL were involved in the acquisition, analysis, and interpretation of data; Ge H and Yuan CL made equal contributions as co-corresponding authors. All authors critically reviewed and approved the final manuscript to be published.
Institutional review board statement: The present study was approved by the Research Ethics Committee of the First People’s Hospital of Lianyungang, No. 202308225.
Informed consent statement: Informed consent statement was finished prior to anticancer therapy.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Not applicable.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Luan Yuan, Department of Oncology, The First People’s Hospital of Lianyungang, No. 6 Zhenhua Road, Lianyungang 222016, Jiangsu Province, China.
Received: March 14, 2025
Revised: May 7, 2025
Accepted: June 26, 2025
Published online: August 24, 2025
Processing time: 159 Days and 20.9 Hours
Revised: May 7, 2025
Accepted: June 26, 2025
Published online: August 24, 2025
Processing time: 159 Days and 20.9 Hours
Core Tip
Core Tip: Immunotherapy can combine with radiotherapy to destroy cancer, either use radiotherapy and immunotherapy at the same time, or treated with radiotherapy first and then use immunotherapy. However, what is the better sequence of radiotherapy and immunotherapy for non-small cell lung cancer patients with brain metastasis? In the present study, we collected the data of non-small cell lung cancer patients with brain metastasis, we found some patients received radiotherapy at first, and then treated with immunotherapy. Those patients did not live as long as patients treated with radiotherapy and immunotherapy at the same time.